05/11/23 4:37 PMNasdaq : CDTX earningsCidara Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial ResultsCidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to save lives and improve the standard of care for patients facing serious diseases, today reported financial results for the first quarterRHEA-AIneutral
05/03/23 4:30 PMNasdaq : CDTX clinical trialCidara Therapeutics Presents New Preclinical Data on Novel Drug-Fc Conjugate CD388 at the 7th International Society for Influenza and Other Respiratory Virus Diseases ConferenceCidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to save lives andRHEA-AIneutral
04/24/23 8:00 AMNasdaq : CDTX fda approvalCidara Therapeutics Receives $20 Million Milestone Payment Following FDA Approval of REZZAYO™CidaraRHEA-AIvery positive
03/31/23 8:00 AMNasdaq : CDTX conferencesCidara Therapeutics to Participate in Upcoming Investor ConferencesCidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that Jeffrey Stein, Ph.D., President and ChiefRHEA-AIneutral
03/23/23 7:12 AMNasdaq : CDTX earningsCidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial ResultsCidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today reported financial results for the three months and fullRHEA-AIpositive
03/22/23 5:23 PMNasdaq : CDTX fda approvalCidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO™ (rezafungin for injection) for the Treatment of Candidemia and Invasive Candidiasis– REZZAYO is a novel, once-weekly, next-generation echinocandin indicated for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options – – REZZAYO is the first new FDA-approved echinocandin in over a decade – SAN DIEGO and PARSIPPANY, N.J.,RHEA-AIvery positive
03/07/23 4:15 PMNasdaq : CDTX clinical trialCidara Therapeutics Presents Preclinical Data on CD73-Targeting Drug-Fc Conjugate at the 2023 ESMO Targeted Anticancer Therapies CongressCidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, presented preclinical data on a CD73-targeting drug-Fc conjugateRHEA-AIneutral
03/07/23 4:01 PMNasdaq : CDTX offeringCidara Therapeutics Announces Closing of Public Offerings of Common Stock and Preferred Stock and Full Exercise of Underwriter’s Option to Purchase Additional Shares in Public Offering of Common StockCidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today announced the closing of its previously announcedRHEA-AIneutral
03/03/23 9:14 AMNasdaq : CDTX offeringCidara Therapeutics Announces Pricing of Public Offerings of Common Stock and Preferred StockCidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today announced the pricing of concurrent but separateRHEA-AIneutral
03/02/23 4:14 PMNasdaq : CDTX offeringCidara Therapeutics Announces Underwritten Public Offerings of Common Stock and Preferred StockCidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today announced concurrent but separate underwritten publicRHEA-AIneutral